Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
Pharmacology, Toxicology and Pharmaceutical Science
7
4%
Neuroscience
6
4%
Nursing and Health Professions
3
2%
Other
15
9%
Unknown
92
58%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 52. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 December 2025.
All research outputs
#1,033,693
of 34,546,575 outputs
Outputs from Lancet Neurology
#668
of 4,649 outputs
Outputs of similar age
#20,091
of 564,002 outputs
Outputs of similar age from Lancet Neurology
#13
of 85 outputs
Altmetric has tracked 34,546,575 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,649 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.4. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 564,002 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 85 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.
